Best Practices in Treatment and Management of Indolent Relapse Multiple Myeloma

Dr Haumschild opens the discussion with Larry Anderson, MD, PhD, and Gabe Hinojosa, PharmD, BCOP, regarding various states of relapse in multiple myeloma.

Medical experts discuss treatment options for indolent and aggressive relapse multiple myeloma.

Drs Haumschild, Anderson, and Hinojosa explore current MM treatment pathways.

Key opinion leaders provide insight on patient considerations when formulating an optimal treatment regimen for multiple myeloma.

Experts highlight the use of 3- and 4-drug regimens for managing relapsed refractory multiple myeloma.

Experts navigate the impact of proteasome inhibitors and anti-CD38 antibody therapies in the relapsed refractory multiple myeloma treatment landscape.

Experts discuss the role of proteasome inhibitors in combination therapy in the management of relapsed indolent multiple myeloma.

Medical experts highlight the significant impact of pharmacists in multiple myeloma treatment pathways.

Medical experts highlight the significant impact of pharmacists in multiple myeloma treatment pathways.

Multiple myeloma clinical pathways and factors affecting patient quality of life are explored by an expert panel.

Social determinants of health inhibit optimal impact of MM treatment.

The medical experts discuss strategies to achieve treatment adherence.

Navigating treatment toxicities is paramount to achieving treatment goals in MM management.

Drs Haumschild, Anderson, and Hinojosa provide their closing thoughts regarding treatment considerations for patients with RRMM.